How to use this page
Interaction evidence for many research peptides is limited. Treat the notes below as prompts for clinician discussion, then read the full monograph for each compound.
GLP-1 / GIP agonists
Agents such as semaglutide, tirzepatide, and related compounds can slow gastric emptying and affect absorption of oral medicines. Discuss timing with a clinician if you take oral medications with a narrow therapeutic window.
Growth-hormone axis secretagogues
Compounds that stimulate GH release (e.g. CJC-1295 variants, ipamorelin, GHRPs) may interact with diabetes management, cortisol dynamics, and concurrent hormone therapies. Monitor glucose if relevant.
Healing & regenerative peptides
Research peptides used in tissue-repair contexts (e.g. BPC-157, TB-500) have limited human interaction data. Caution is commonly discussed alongside anticoagulants, active cancer treatment, and surgery timing — confirm with your care team.
Stacks and polypharmacy
Combining multiple peptides increases uncertainty. Prefer documented protocols, introduce one change at a time, and record timing, dose, and any adverse effects. Use our protocols and comparison tools as educational starting points only.
Practical checklist
- List every medicine, supplement, and peptide you use.
- Flag anticoagulants, diabetes drugs, and hormone therapies.
- Check each peptide profile’s contraindications section.
- Ask a clinician before stacking or changing doses.